Survey Reveals Wide Variation in Anticoagulation After Venous Stenting

When interventional radiologists thread a metal stent into a narrowed or blocked central vein, they face an immediate question with no settled answer: which blood-thinning drugs should the patient take afterward, at what dose, and for how long? A new survey of vascular specialists, published in CVIR Endovascular, offers the most detailed snapshot to date of how physicians actually answer that question in daily practice, and the picture it paints is one of broad, systematic variation rather than consensus.

It was distributed by direct email to attending physicians at 668 programs with vascular expertise, promoted on LinkedIn and X, and circulated through society forums including the Society of Interventional Radiology, the Society for Vascular Surgery, and the American Venous Forum. Each respondent was limited to a single submission. In total, 129 physicians completed the survey, and interventional radiologists made up 94 percent of the sample, with interventional cardiologists, hematologists, and vascular surgeons each accounting for only 2 percent.

The survey asked respondents to describe their preferred antithrombotic regimen after venous stent placement, stratifying answers for interventions in the superior vena cava and upper extremity versus the inferior vena cava and lower extremity. Physicians chose from fifteen standardized therapeutic combinations covering anticoagulants such as low molecular weight heparin, warfarin, and direct oral anticoagulants, alongside single or dual antiplatelet therapy. The investigators then used descriptive statistics and single proportion tests to determine whether any regimen represented a statistically significant majority preference, with a significance threshold of 50 percent and a p value cutoff of 0.05.

The results showed no regimen reached that majority threshold in either anatomic territory, but clear leading preferences emerged. For superior vena cava and upper extremity stenting, the most common choice was a direct oral anticoagulant combined with single antiplatelet therapy, selected by 39 of 117 respondents, or 33 percent in the results analysis. For inferior vena cava and lower extremity stenting, low molecular weight heparin plus single antiplatelet therapy led, chosen by 12 of 38 respondents in the abstract summary and described as 31 percent of respondents in the results section, followed by a direct oral anticoagulant with single antiplatelet therapy at 23 percent. Comparing the two territories, the direct oral anticoagulant combination was selected 9 percent more often for upper extremity disease, while the heparin-based combination was chosen 20 percent more often for lower extremity disease.

Duration of therapy proved equally revealing. For superior vena cava interventions, the most common answer was lifelong aspirin, chosen by 10 respondents or 43 percent, three months for non-aspirin antiplatelet agents such as clopidogrel, chosen by 23 respondents or 52 percent, and six months for anticoagulants, chosen by 32 respondents or 44 percent. For inferior vena cava and lower extremity interventions, the pattern was similar but not identical: 40 percent recommended lifelong aspirin, 53 percent favored three months for non-aspirin antiplatelets, and anticoagulant duration split evenly between six and twelve months, with 7 respondents or 30 percent favoring each. In other words, aspirin tends to be prescribed indefinitely, non-aspirin antiplatelets for a fixed short course, and anticoagulants for an intermediate window that varies by physician.

Beyond agent and duration, the survey probed which patient factors drive changes to the regimen. Fifty-four potential factors were tested against a reference proportion of 0.279, the average rate of regimen change observed when any adverse event occurs, with a Bonferroni correction applied for multiple comparisons. Eight variables significantly influenced anticoagulation selection for upper extremity interventions: concurrent anticoagulation, a history of deep vein thrombosis elsewhere, renal insufficiency, a hypercoagulable state due to malignancy, intracranial metastatic disease, antiphospholipid syndrome, Factor V Leiden mutation, and the cost of medication. For lower extremity interventions, only the cost of medications reached statistical significance. The authors note that respondents appear to risk-stratify patients for stent thrombosis based on hypercoagulable conditions while weighing hemorrhagic risk in cases such as intracranial malignancy.

The clinical backdrop explains why this variation matters. Venous occlusive disease, encompassing venous stenosis, compression, fibrotic change, or residual organized thrombus, is increasingly treated with venous stenting to relieve the swelling, limb edema, and facial swelling that accompany chronic venous insufficiency. Randomized trials, cohort studies, and meta-analyses show that stenting improves venous patency and quality of life compared with angioplasty or medical management alone, and the Society of Interventional Radiology recommends venous stent placement for chronic iliofemoral venous obstruction. Yet the chief concern is long-term patency: rates of in-stent restenosis or stent thrombosis may reach 28 percent after one year and 56 percent after five years. Antithrombotic therapy is the main lever physicians can pull to protect the stent, but no prospective randomized controlled trial has ever compared regimens or durations for stent patency.

What evidence does exist is limited and largely observational. Small prospective cohorts have found that direct oral anticoagulants produce stent patency and complication rates similar to warfarin, and that rethrombosis rates on anticoagulation did not differ between three and twelve months, with the highest rethrombosis risk concentrated in the first few months after placement. Retrospective studies support the use of both anticoagulation and antiplatelet therapy to reduce acute stent rethrombosis, and there is growing evidence that inflammation contributes to venous thrombosis, with increased risk in the setting of systemic infection, surgery, obesity, and malignancy. Both low molecular weight heparin and direct oral anticoagulants show similar bleeding and rethrombosis profiles, but low molecular weight heparin may have an anti-inflammatory role that reduces acute thrombotic risk after stenting. Before the current survey, the only prior poll on the topic was a 2018 expert consensus of 106 international specialists focused on iliac stenting in May-Thurner syndrome, which concluded that six to twelve months of anticoagulation is appropriate, that low molecular weight heparin is the preferred acute agent for the first six weeks, and that anticoagulation should continue lifelong in patients with recurrent deep vein thrombosis; the role of antiplatelet agents was not addressed.

The survey’s authors are candid about its limits. The sample was small for lower extremity management questions, skewed toward physicians earlier in their careers, and dominated by interventional radiologists, which the authors explicitly state limits generalizability. International participation was limited, and healthcare infrastructure differences may confound drug selection in ways the survey did not capture. Medication cost emerged as an important factor, but other influences on drug choice, duration, and patient compliance were not assessed. Practice settings among respondents included academic centers at 43.4 percent, community hospitals at 53.4 percent, and outpatient-based labs at 3.1 percent, and most respondents reported performing between 11 and 50 central vein reconstructions. Despite these constraints, the authors describe the work as the largest, most recent, and only analysis of current antithrombotic practice after venous stenting in venous occlusive disease.

The takeaway for the field is less a guideline than a baseline. The study documents that while most specialists favor some combination of anticoagulation and a single antiplatelet agent in the acute period after venous stenting, both the choice of agent and the duration of therapy remain widely variable, shaped more by individual risk assessment and drug cost than by evidence. The authors position the findings as epidemiological groundwork: by establishing what regimens are actually in use, the survey provides the justification and the comparator arms for the comparative safety and efficacy trials that have so far never been done, and which would be needed before a formal therapeutic guideline for post-stent anticoagulation can be written.

Subject of Research: Physician survey of anticoagulation and antiplatelet regimens prescribed after venous stent placement for venous occlusive disease

Article Title: Anticoagulation practices in venous occlusive disease after stent placement

Article References: Ayman, O., Antonescu, O., Campbell, W. A., IV, Lim, H., Lee, E., Chick, J. F. B., Shin, D., & Makary, M. S. (2026). Anticoagulation practices in venous occlusive disease after stent placement. CVIR Endovascular, 9(1), Article 129. https://doi.org/10.1186/s42155-026-00763-y

Image Credits: AI Generated

DOI: 10.1186/s42155-026-00763-y

Keywords: venous occlusive disease, venous stenting, anticoagulation, antiplatelet therapy, direct oral anticoagulants, low molecular weight heparin, stent patency, interventional radiology, physician survey, deep vein thrombosis, inferior vena cava, superior vena cava